Appeal No. 2004-1761 Page 3
Application No. 10/044,807
The specification also discloses that the gene corresponding to SEQ ID NO:1
has a total of seven polymorphic positions. See page 18. Presumably based on these
polymorphisms, the specification discloses that
the present sequences can be used in restriction fragment length
polymorphism (RFLP) analysis to identify specific individuals. In this
technique, an individual’s genomic DNA is digested with one or more
restriction enzymes, and probed on a Southern blot to yield unique bands
for identification (as generally described in U.S. Patent No. 5,272,057,
incorporated herein by reference). In addition, the sequences of the
present invention can be used to provide polynucleotide reagents, e.g.
PCR primers, targeted to specific loci in the human genome, which can
enhance the reliability of DNA-based forensic identifications by, for
example, providing another “identification marker” (i.e., another DNA
sequence that is unique to a particular individual). Actual base sequence
information can be used for identification as an accurate alternative to
patterns formed by restriction enzyme generated fragments.
Page 12.
The specification also discloses that “suitably labeled NHP nucleotide probes
may be used to screen a human genomic library using appropriately stringent conditions
or PCR. The identification and characterization of human genomic clones is helpful for
identifying polymorphisms . . . , determining the genomic structure of a given
locus/allele, and designing diagnostic tests.” Pages 11-12.
The specification discloses that “[t]he NHP or NHP peptides, NHP fusion
proteins, NHP nucleotide sequences, host cell expression systems, antibodies,
antagonists, agonists and genetically engineered cells and animals can be used for
screening for drugs . . . effective in the treatment of the symptomatic or phenotypic
manifestations of perturbing the normal function of a NHP in the body.” Page 12. Or
“the NHP products can be used as therapeutics. For example, soluble derivatives such
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007